Genetic insight and therapeutic targets in squamous-cell lung cancer

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Oncogene

• Publication date

  2012-01-23

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/onc.2011.640PMID 22266863
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

  2012cited by this paper
• Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.

  2011cited by this paper
• Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer

  2011cited by this paper
• Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

  2011cited by this paper
• Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

  2010cited by this paper
• Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

  2010cited by this paper
• Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.

  2010cited by this paper
• A Therapeutic Target for Smoking-Associated Lung Cancer

  2010cited by this paper
• Evidence That SOX2 Overexpression Is Oncogenic in the Lung

  2010cited by this paper
• Sex Determining Region Y-Box 2 (SOX2) Is a Potential Cell-Lineage Gene Highly Expressed in the Pathogenesis of Squamous Cell Carcinomas of the Lung

  2010cited by this paper
• SOX2 Is an Oncogene Activated by Recurrent 3q26.3 Amplifications in Human Lung Squamous Cell Carcinomas

  2010cited by this paper
• Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

  2010cited by this paper
• Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer

  2010cited by this paper
• Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.

  2010cited by this paper
• Fibroblast growth factor signalling: from development to cancer

  2010cited by this paper
• Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

  2010cited by this paper
• FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.

  2010cited by this paper
• Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.

  2010cited by this paper
• F1000 highlights

  2009cited by this paper
• SOX2 Is an Amplified Lineage Survival Oncogene in Lung and Esophageal Squamous Cell Carcinomas

  2009cited by this paper
• Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer

  2009cited by this paper
• Quantification of the yeast transcriptome by single-molecule sequencing

  2009cited by this paper
• Fibroblast Growth Factor (FGF) and FGF Receptor-Mediated Autocrine Signaling in Non-Small-Cell Lung Cancer Cells

  2009cited by this paper
• Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

  2009cited by this paper
• Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions.

  2009cited by this paper
• Comprehensive genomic characterization defines human glioblastoma genes and core pathways

  2009cited by this paper
• Screening for epidermal growth factor receptor mutations in lung cancer.

  2009cited by this paper
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

  2009cited by this paper
• BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.

  2008cited by this paper
• FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival.

  2008cited by this paper
• A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

  2008cited by this paper
• Single-Molecule DNA Sequencing of a Viral Genome

  2008cited by this paper
• Comprehensive genomic characterization defines human glioblastoma genes and core pathways

  2008cited by this paper
• Drug-sensitive FGFR2 mutations in endometrial carcinoma

  2008cited by this paper
• Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

  2007cited by this paper
• High-throughput oncogene mutation profiling in human cancer

  2007cited by this paper
• EGF Receptor Gene Mutations Are Common in Lung Cancers From “Never Smokers” and Are Associated With Sensitivity of Tumors to Gefitinib and Erlotinib

  2006cited by this paper
• Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

  2006cited by this paper
• Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing

  2006cited by this paper
• Accurate Multiplex Polony Sequencing of an Evolved Bacterial Genome

  2005cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

  2004cited by this paper
• Discoidin Domain Receptor 2 Interacts with Src and Shc following Its Activation by Type I Collagen*

  2002cited by this paper
• Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas

  1999cited by this paper

• Impact of the use of antibiotics on the clinical response to immune checkpoint inhibitors in patients with non-small cell lung cancer

  2022cites this paper
• Construction of a prognostic immune-related lncRNA model and identification of the immune microenvironment in middle- or advanced-stage lung squamous carcinoma patients

  2022cites this paper
• USP28: Oncogene or Tumor Suppressor? A Unifying Paradigm for Squamous Cell Carcinoma

  2021cites this paper
• Long Overall Survival in a Case of Refractory Stage IV Squamous Cell Carcinoma of Lung Treated with Personalized De Novo Combination Regimen

  2020cites this paper
• The Papanicolaou Society of Cytopathology System for Reporting Respiratory Cytology

  2019cites this paper
• Informe de Posicionamiento Terapéutico de osimertinib (Tagrisso®) en el tratamiento del cáncer de pulmón no microcítico en primera línea

  2019influential citation
• Informe de Posicionamiento Terapéutico de alectinib (Alecensa®) en el tratamiento de cáncer de pulmón no microcítico

  2018influential citation
• Category V: Suspicious for Malignancy

  2018cites this paper
• A curated target gene pool assisting disease prediction and patient-specific biomarker selection for lung squamous cell carcinoma

  2018cites this paper
• Informe de Posicionamiento Terapéutico de alectinib (Alecensa®) en el tratamiento de cáncer de pulmón no microcítico en primera línea

  2018cites this paper
• Informe de Posicionamiento Terapéutico de atezolizumab (Tecentriq®) en el tratamiento de cáncer de pulmón no microcítico

  2018cites this paper
• Informe de Posicionamiento Terapéutico de ceritinib (Zykadia®) en el tratamiento de cáncer de pulmón no microcítico en primera línea

  2018cites this paper
• Molecular Targets in Non-Small Cell Lung Cancer.

  2017cites this paper
• Interferon induced transmembrane protein 3 regulates the growth and invasion of human lung adenocarcinoma

  2017cites this paper
• Clinicopathologic Features of Advanced Squamous NSCLC.

  2016cites this paper
• Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment

  2016cites this paper
• KRAS Mutation in Small Cell Lung Carcinoma and Extrapulmonary Small Cell Cancer.

  2016cites this paper
• A sarcoidosis‐like granuloma reaction in the lymph nodes of a patient with lung squamous cancer: from stasis to the invasive phase with FGFR1 gene amplification

  2016cites this paper
• Targeting the KRAS Pathway in Non-Small Cell Lung Cancer.

  2016cites this paper
• The use of biomarkers in the treatment of non-small cell lung cancer

  2016cites this paper
• Signalisation nucléaire de l'IGF-1R et résistance aux thérapies anti-EGFR dans les cancers du poumon

  2016cites this paper
• Small molecule discoidin domain receptor kinase inhibitors and potential medical applications.

  2015cites this paper
• PIAS3 expression in squamous cell lung cancer is low and predicts overall survival

  2015cites this paper
• Non-small-cell lung cancer

  2015cites this paper
• Vers une classification moléculaire du cancer bronchique

  2014cites this paper
• Identification of serum proteome components associated with progression of non-small cell lung cancer.

  2014cites this paper
• Antitumor Efficacy of the Anti-Interleukin-6 (IL-6) Antibody Siltuximab in Mouse Xenograft Models of Lung Cancer

  2014cites this paper
• Rapid onset lung squamous cell carcinoma with prominent peritoneal carcinomatosis and an eosinophilic leukemoid reaction, with coexistence of the BRAF V600E and oncogenic KRAS G12A mutations: A case report

  2014cites this paper
• Integration of genomic data analysis for demonstrating potential targets in the subgroup populations of squamous cell lung cancer patients.

  2014influential citation
• Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype

  2014cites this paper
• Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.

  2014cites this paper
• Molecular profiling in non-small cell lung cancer: a step toward personalized medicine.

  2013cites this paper
• [Regional molecular genetics centers in thoracic oncology: what and who should be tested?].

  2013cites this paper
• Lung Cancer 2 Genetics and biomarkers in personalisation of lung cancer treatment

  2013cites this paper
• Plateformes de biologie moléculaire en oncologie thoracique : quelles recherches, pour qui ?

  2013cites this paper
• PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine

  2013cites this paper
• Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma

  2013cites this paper
• [Allelic imbalance in patients with non-small cell lung cancer].

  2013cites this paper
• Genetics and biomarkers in personalisation of lung cancer treatment.

  2013cites this paper
• Modulation of sensitivity to antitumor agents by targeting the MAPK survival pathway.

  2012cites this paper